Although activation of NF-κB was also described to lead to a decreased sensitivity of cancer cells against chemotherapeutic treatment [63, 64], our present findings propose a subunit specificity of NF-κB in terms of chemoresistance. The gene discussed is NFKB1; the disease is cancer.